PL2903968T3 - Inhibitory demetylaz histonowych - Google Patents
Inhibitory demetylaz histonowychInfo
- Publication number
- PL2903968T3 PL2903968T3 PL13770928T PL13770928T PL2903968T3 PL 2903968 T3 PL2903968 T3 PL 2903968T3 PL 13770928 T PL13770928 T PL 13770928T PL 13770928 T PL13770928 T PL 13770928T PL 2903968 T3 PL2903968 T3 PL 2903968T3
- Authority
- PL
- Poland
- Prior art keywords
- inhibitors
- histone demethylases
- demethylases
- histone
- Prior art date
Links
- 102000008157 Histone Demethylases Human genes 0.000 title 1
- 108010074870 Histone Demethylases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261708806P | 2012-10-02 | 2012-10-02 | |
| DKPA201200599 | 2012-10-02 | ||
| US201361770050P | 2013-02-27 | 2013-02-27 | |
| DKPA201370112 | 2013-02-27 | ||
| EP13770928.3A EP2903968B1 (en) | 2012-10-02 | 2013-10-01 | Inhibitors of histone demethylases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2903968T3 true PL2903968T3 (pl) | 2017-05-31 |
Family
ID=52781382
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13770928T PL2903968T3 (pl) | 2012-10-02 | 2013-10-01 | Inhibitory demetylaz histonowych |
| PL15200672T PL3023415T3 (pl) | 2012-10-02 | 2013-10-01 | Inhibitory demetylaz histonowych |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15200672T PL3023415T3 (pl) | 2012-10-02 | 2013-10-01 | Inhibitory demetylaz histonowych |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US20150203453A1 (pl) |
| EP (3) | EP3023415B1 (pl) |
| JP (2) | JP6530313B2 (pl) |
| KR (1) | KR102160320B1 (pl) |
| CN (2) | CN104981458B (pl) |
| AP (1) | AP2015008389A0 (pl) |
| AU (1) | AU2018200876C1 (pl) |
| BR (1) | BR112015007083A2 (pl) |
| CA (2) | CA3095019C (pl) |
| CL (1) | CL2015000829A1 (pl) |
| CR (1) | CR20150217A (pl) |
| CY (1) | CY1118695T1 (pl) |
| DK (1) | DK2903968T3 (pl) |
| EA (1) | EA030698B1 (pl) |
| ES (2) | ES2654143T3 (pl) |
| HK (1) | HK1215710A1 (pl) |
| HR (1) | HRP20170358T1 (pl) |
| HU (1) | HUE033380T2 (pl) |
| IL (2) | IL237831A (pl) |
| LT (1) | LT2903968T (pl) |
| MD (1) | MD20150043A2 (pl) |
| ME (1) | ME02597B (pl) |
| MX (1) | MX2015003959A (pl) |
| NZ (1) | NZ706635A (pl) |
| PE (1) | PE20150998A1 (pl) |
| PH (2) | PH12015500730A1 (pl) |
| PL (2) | PL2903968T3 (pl) |
| PT (2) | PT3023415T (pl) |
| RS (1) | RS55764B1 (pl) |
| SG (2) | SG10201703682YA (pl) |
| SI (2) | SI2903968T1 (pl) |
| SM (2) | SMT201700109T1 (pl) |
| WO (1) | WO2014053491A1 (pl) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015003959A (es) | 2012-10-02 | 2015-11-16 | Epitherapeutics Aps | Inhibidores de histona demetilasas. |
| ES2670864T3 (es) | 2013-02-27 | 2018-06-01 | Gilead Sciences, Inc. | Inhibidores de histonas desmetilasas |
| AR099890A1 (es) * | 2014-03-31 | 2016-08-24 | Epitherapeutics Aps | Inhibidores de histona demetilasas |
| MX2017002451A (es) | 2014-08-27 | 2017-05-23 | Gilead Sciences Inc | Compuestos y metodos para inhibir histona desmetilasas. |
| JP6723663B2 (ja) | 2014-09-17 | 2020-07-15 | ă»ă«ăžăŒăł ăŻăȘăłăăŁă»ă« ăȘă”ăŒăïŒă€ăłăŻïŒ | ăăčăăłăăĄăă©ăŒăŒé»ćźłć€ |
| US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| KR20170048591A (ko) | 2014-09-17 | 2017-05-08 | ì ì 윎í°ì 늏ììč, ìžíŹ. | íì€í€ ë°ë©ížëŒì ì”ì ì |
| MX2017005346A (es) | 2014-10-29 | 2017-08-02 | Dong A St Co Ltd | Nuevos compuestos de piridopirimidinona para modular la actividad catalitica de histona lisina desmetilasas (kdm). |
| JP6788584B2 (ja) * | 2014-10-31 | 2020-11-25 | ăă”ăă„ăŒă»ăă ă€ăłăčăăŁăă„ăŒă ăȘă ăăŻăăăžăŒ | ïŒŁïœïœïœïœïœă«ă€ăăŠăźè¶ 䞊ćăłăłăăăăȘăąă«éșäŒćŠ |
| AU2016250099A1 (en) * | 2015-04-14 | 2017-10-12 | Gilead Sciences, Inc. | Methods of treating hepatitis B virus |
| US10206930B2 (en) * | 2015-08-14 | 2019-02-19 | New York University | Methods for treating T-cell acute lymphoblastic leukemia |
| WO2017099829A1 (en) | 2015-12-11 | 2017-06-15 | The General Hospital Corporation | Compositions and methods for treating drug-tolerant glioblastoma |
| CN108698997A (zh) | 2015-12-28 | 2018-10-23 | è”ć°ćșć æèè”ć°ç ç©¶ć Źćž | ç»èçœè±çČćșé ¶æć¶ć |
| ES2921009T3 (es) * | 2016-03-15 | 2022-08-16 | Celgene Quanticel Res Inc | Inhibidores de desmetilasas de histonas |
| WO2017198785A1 (en) * | 2016-05-18 | 2017-11-23 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Oxime derivatives useful as inhibitors of histone demethylase kdm4c |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| EP3463469B1 (en) | 2016-05-27 | 2023-12-13 | Gilead Sciences, Inc. | Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | Ù Ű±ÙۚۧŰȘ ŰšÙ۱ÙÙÙŰČÙÙ ŰšÙۧ ۧ۳ŰȘŰšŰŻŰ§Ù Ùۧ۳ŰȘŰźŰŻŰ§Ù Ű§ŰȘÙۧ |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | í늏ìì Œ ë°ìŽì€ìŹìŽìžìì€ ìžìœíŹë ìŽí°ë | Bí ê°ìŒ ë°ìŽëŹì€ êČë ëŽì ìžì ììŽì ëíŽ íčìŽì ìž ìĄ°ìë ë©ê°ëŽíŽë ìì |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | çŸććșć©ç§ćžèĄä»œæéć Źćž | æżè«ŸçŠéćæé èș(tenofovir alafenamide)äčæ¶ć |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | Ù Ű±ÙۚۧŰȘ ÙŰčÙۧۏ ۄ۔ۧۚ۩ ŰšŰčŰŻÙÙ ÙÙ۱ÙŰł ۧÙۧÙŰȘÙۧۚ ۧÙÙŰšŰŻÙ b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | Ù Ű«ŰšŰ·Ű§ŰȘ pd-1/pd-l1 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3âČ3âČ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | æ·ć ć ±ććœææșććŠäžçç©ććŠç 究æ | 掻ćstingèœŹæ„èçœçć ·æèŠé žé Żéźç2â3âçŻç¶äșæ žè·é ž |
| JP7062792B2 (ja) | 2018-02-13 | 2022-05-06 | ăźăȘăąăŒă ă”ă€ăšăłă·ăŒășïŒ ă€ăłăłăŒăăŹă€ăăă | ïœïŒïŒïŒïœïœïŒïœïŒé»ćźłć€ |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | æ·ć ç§ćžéąææ©ććžèçç©ććžç 究æ | ïŒïŒïŒïŒâç°äșæ žè·é ž |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | æ·ć ç§ćžéąææ©ććžèçç©ććžç 究æ | 2'3'-ç°äșæ žè·é ž |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | æ·ć ç§ćžéąææ©ććžèçç©ććžç 究æ | 3'3'-ç°äșæ žè·é ž |
| CN108186643B (zh) * | 2018-04-09 | 2021-04-20 | ćŸć·ç»Žćș·çç©ç§ææéć Źćž | äžç§ć ·æććæéȘšèç€ćæçèŻç©ç»ćç©ćć ¶ćșçš |
| CN108464984A (zh) * | 2018-04-09 | 2018-08-31 | ćŸć·ç»Žćș·çç©ç§ææéć Źćž | äžç§æČ»çéȘšèç€çèĄšè§éäŒ èŻç© |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| CN108530381B (zh) * | 2018-05-07 | 2021-09-21 | äžæ”·ç§æć€§ćŠ | äžç§ç±é °èșé Żć¶ć€äșèșèĄçç©çæčæł |
| JP2021530444A (ja) | 2018-06-28 | 2021-11-11 | ăăâăăĄăŒăăŒ ăăŁăłă”ăŒ ă€ăłăčăăŁăă„ăŒăïŒă€ăłăłăŒăăŹă€ăăă | ćșćœąăăăłæ¶ČäœæȘæ§ç ć€ă«ăăăć€éïœïœïœ ïœçŽ°èă§ăźè€æ°æćăźæšçć |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | ćć©ćŸ·ç§ćŠć Źćž | Pd-1/pd-l1æć¶ć |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| JP2021534084A (ja) * | 2018-08-06 | 2021-12-09 | ăăâăăĄăŒăăŒ ăăŁăłă”ăŒ ă€ăłăčăăŁăă„ăŒăïŒă€ăłăłăŒăăŹă€ăăă | ăăčăăłăăĄăă©ăŒăŒïŒé»ćźłć€ăăăłăăźäœżçš |
| CN109234313A (zh) * | 2018-09-25 | 2019-01-18 | äžæ”·äș€é性ćŠć»ćŠéąéć±çŹŹäčäșșæ°ć»éą | ć ±èœŹæ蜜äœćć ¶ćšæéȘšèç€èŻç©äžçćșçš |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | êžžëŠŹì ë ìŹìŽìžììŠ, ìžìœíŹë ìŽí°ë | Pd-1/pd-l1 ì”ì ì |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | ćć©ćŸ·ç§ćŠć Źćž | ć ·æhpk1æć¶æŽ»æ§çć代ç6-æ°źæèŻćč¶ćȘćććç© |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3âČ3âČ-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | çŸććșć©ç§ćžèĄä»œæéć Źćž | éĄéžćé«èȘżçŻćäčćșé«ćœąćŒ |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | çŸććșć©ç§ćžèĄä»œæéć Źćž | éĄéžćé«èȘżçŻćäčćșé«ćœąćŒ |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | çŸććșć©ç§ćžèĄä»œæéć Źćž | ç¶ć代äčçŻćČćé źćç©ćć ¶çšé |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| CN110652589A (zh) * | 2019-10-12 | 2020-01-07 | äžćœäșșæ°è§ŁæŸćéććć»ć€§ćŠ | Gasc1æć¶ććšć¶ć€æČ»çèççèŻç©äžçćșçš |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| CN111073900B (zh) * | 2019-12-09 | 2023-05-02 | æž©æ°éŁćéćąèĄä»œæéć Źćž | äžç§æé«çȘć éèèćèČæççæčæł |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | ProfĂĄrmacos de nucleĂłsidos 4Â-c-sustituidos-2-halo-2Â-deoxiadenosina y mĂ©todos de preparaciĂłn y uso de los mismos |
| KR20230029659A (ko) | 2020-05-26 | 2023-03-03 | ê°ë¶ìí€ê°ìŽì€ í€ëŠŹì€ì€ | ì ë©Žììì± ìžíŹ |
| US12110305B2 (en) | 2020-08-07 | 2024-10-08 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| CN111905102A (zh) * | 2020-09-04 | 2020-11-10 | çŠć»șć»ç§ć€§ćŠéć±çŹŹäžć»éą | Ezh2æć¶ććšæČ»çè¶èŽšç€äžçćșçš |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | çŸććșć©ç§ćžèĄä»œæéć Źćž | ä»çœçŽ 2-Fcèćèçœćäœżçšæčæł |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | êžžëŠŹì ë ìŹìŽìžììŠ, ìžìœíŹë ìŽí°ë | ëìì€êžëŠŹìžëĄ€ í€ëì ìĄ°ì íí©ëŹŒ |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ăźăȘăąăŒă ă”ă€ăšăłă·ăŒășïŒ ă€ăłăłăŒăăŹă€ăăă | ăžăąă·ă«ă°ăȘăšă«ăłăŒă«ïŒïœïœïœïœïœïœïœïœïœïœ ïœïœïœïœïŒăăăŒăŒèȘżçŻććç© |
| CN114907317B (zh) * | 2022-06-01 | 2023-06-13 | éć·ć€§ćŠ | äžç§ćĄć-äčçŻćș-ćŒçé žèĄçç©ćć ¶ć¶ć€æčæłććșçš |
| CN115806522B (zh) * | 2022-11-24 | 2025-05-13 | äžćœèŻç§ć€§ćŠ | äžç§ć代ćĄć¶èĄçç©ćć ¶ćșçš |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| GB8717374D0 (en) * | 1987-07-22 | 1987-08-26 | Smith Kline French Lab | Pharmaceutically active compounds |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| NZ334821A (en) | 1996-08-30 | 2000-12-22 | Novartis Ag | Method for producing epothilones |
| DE69724269T2 (de) | 1996-09-06 | 2004-06-09 | Obducat Ab | Verfahren fĂŒr das anisotrope Ă€tzen von strukturen in leitende materialien |
| US5874438A (en) | 1996-10-11 | 1999-02-23 | Bayer Aktiengesellschaft | 2,2'-bridged bis-2,4-diaminoquinazolines |
| CN100344627C (zh) | 1996-11-18 | 2007-10-24 | çç©ææŻç 究æéć Źćž(Gbf) | ććĄéçŽ căć ¶ć¶ć€æčæłä»„ćäœäžșç»èæć¶ććæ€ç©äżæ€ćçćșçš |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| ATE307123T1 (de) | 1998-02-25 | 2005-11-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
| EP1135470A2 (en) | 1998-11-20 | 2001-09-26 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6620811B2 (en) * | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| CA2478374C (en) | 2002-03-13 | 2009-01-06 | Eli M. Wallace | N3 alkylated benzimidazole derivatives as mek inhibitors |
| BRPI0512261A (pt) | 2004-06-17 | 2008-02-26 | Wyeth Corp | antagonistas de receptor de hormĂnio liberador de gonadotropina |
| WO2008002671A2 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| JPWO2009119088A1 (ja) * | 2008-03-25 | 2011-07-21 | æŠç°èŹćć·„æ„æ ȘćŒäŒç€Ÿ | è€çŽ ç°ććç© |
| SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | ŰȘ۱ÙÙۚ۩ Ű”ÙŰŻÙۧÙÙŰ© ŰŹŰŻÙŰŻŰ© Ù Ű¶Ű§ŰŻŰ© ÙÙŰłŰ±Ű·Ű§Ù |
| MX2011004553A (es) * | 2008-10-29 | 2011-07-20 | Sirtris Pharmaceuticals Inc | Piridina, piridina biciclica y analogos relacionados como moduladores de sirtuina. |
| WO2011017583A1 (en) | 2009-08-07 | 2011-02-10 | The Wistar Institute | Compositions containing jarid1b inhibitors and methods for treating cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | ĐĐ°ŃŃĐŸŃŃĐČĐ°ĐœĐœŃ c-met-ĐŒĐŸĐŽŃĐ»ŃŃĐŸŃŃĐČ ĐČ ĐșĐŸĐŒĐ±ŃĐœĐ°ŃŃŃ Đ· ŃĐ”ĐŒĐŸĐ·ĐŸĐ»ĐŸĐŒŃĐŽĐŸĐŒ ŃĐ°/Đ°Đ±ĐŸ ĐżŃĐŸĐŒĐ”ĐœĐ”ĐČĐŸŃ ŃĐ”ŃĐ°ĐżŃŃŃ ĐŽĐ»Ń Đ»ŃĐșŃĐČĐ°ĐœĐœŃ ŃĐ°ĐșŃ | |
| PH12015502575A1 (en) | 2010-03-10 | 2017-04-24 | Incyte Corp | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| US9365553B2 (en) * | 2010-05-27 | 2016-06-14 | Aska Pharmaceutical Co., Ltd. | Heterocyclic compound and H1 receptor antagonist |
| WO2012007008A1 (en) * | 2010-07-15 | 2012-01-19 | Epitherapeutics Aps | Inhibitors of hdme |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| PE20141322A1 (es) | 2011-03-25 | 2014-10-05 | Glaxosmithkline Intellectual Property (N 2) Limited | Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina |
| BR112014003382B1 (pt) | 2011-08-15 | 2022-03-15 | University Of Utah Research Foundation | AnĂĄlogos de (e)-n-(1-feniletilideno) benzo-hidrazida substituĂda como inibidores de histona desmetilase e composiçÔes farmacĂȘuticas compreendendo-os |
| JP2013107880A (ja) | 2011-10-27 | 2013-06-06 | Astellas Pharma Inc | ïŒźâăăšăă«ăăłășăąăăèȘć°äœ |
| JP6164556B2 (ja) * | 2011-12-01 | 2017-07-19 | ćœç«ć€§ćŠæłäșș ćèć€§ćŠ | éçčç°çè éç©ăäœæžăăăæŸć°æ§æšèăăȘăăăăäœèŁœçšèŹć€ |
| CN102585150B (zh) * | 2012-02-01 | 2013-09-04 | ćć ŽćŠéą | ç»ç©æ¶é„°çšéŽçŠ»ćæ°Žæ§èæ°šé ŻćæŁäœçć¶ć€æčæł |
| WO2013123411A1 (en) | 2012-02-17 | 2013-08-22 | Board Of Regents, The University Of Texas System | Methods for diagnosing and treating cancer |
| WO2013129435A1 (ja) * | 2012-02-28 | 2013-09-06 | ććçșé ”ăăȘăłæ ȘćŒäŒç€Ÿ | çžźç°ăăȘăă§ăłèȘć°äœ |
| MX2015003959A (es) | 2012-10-02 | 2015-11-16 | Epitherapeutics Aps | Inhibidores de histona demetilasas. |
| ES2834959T3 (es) | 2012-12-06 | 2021-06-21 | Celgene Quanticel Res Inc | Inhibidores de histona desmetilasa |
| US9617242B2 (en) | 2012-12-19 | 2017-04-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| HK1210611A1 (en) | 2012-12-21 | 2016-04-29 | Quanticel Pharmaceuticals Inc | Histone demethylase inhibitors |
| ES2670864T3 (es) | 2013-02-27 | 2018-06-01 | Gilead Sciences, Inc. | Inhibidores de histonas desmetilasas |
| HRP20171609T1 (hr) | 2013-03-15 | 2017-12-15 | Quanticel Pharmaceuticals Inc | Inhibitori histon demetilaze |
| US9505767B2 (en) | 2013-09-05 | 2016-11-29 | Genentech, Inc. | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors |
| AR099890A1 (es) | 2014-03-31 | 2016-08-24 | Epitherapeutics Aps | Inhibidores de histona demetilasas |
-
2013
- 2013-10-01 MX MX2015003959A patent/MX2015003959A/es unknown
- 2013-10-01 SI SI201330511A patent/SI2903968T1/sl unknown
- 2013-10-01 SM SM20170109T patent/SMT201700109T1/it unknown
- 2013-10-01 LT LTEP13770928.3T patent/LT2903968T/lt unknown
- 2013-10-01 ES ES15200672.2T patent/ES2654143T3/es active Active
- 2013-10-01 BR BR112015007083A patent/BR112015007083A2/pt active Search and Examination
- 2013-10-01 EP EP15200672.2A patent/EP3023415B1/en active Active
- 2013-10-01 HR HRP20170358TT patent/HRP20170358T1/hr unknown
- 2013-10-01 PE PE2015000454A patent/PE20150998A1/es not_active Application Discontinuation
- 2013-10-01 HK HK16103714.1A patent/HK1215710A1/zh unknown
- 2013-10-01 CA CA3095019A patent/CA3095019C/en active Active
- 2013-10-01 SG SG10201703682YA patent/SG10201703682YA/en unknown
- 2013-10-01 KR KR1020157011211A patent/KR102160320B1/ko active Active
- 2013-10-01 SI SI201330878T patent/SI3023415T1/en unknown
- 2013-10-01 EP EP16186022.6A patent/EP3150582A1/en not_active Withdrawn
- 2013-10-01 NZ NZ706635A patent/NZ706635A/en not_active IP Right Cessation
- 2013-10-01 PT PT152006722T patent/PT3023415T/pt unknown
- 2013-10-01 PT PT137709283T patent/PT2903968T/pt unknown
- 2013-10-01 CA CA2885969A patent/CA2885969C/en active Active
- 2013-10-01 EP EP13770928.3A patent/EP2903968B1/en active Active
- 2013-10-01 AP AP2015008389A patent/AP2015008389A0/xx unknown
- 2013-10-01 MD MDA20150043A patent/MD20150043A2/ro not_active Application Discontinuation
- 2013-10-01 ME MEP-2017-46A patent/ME02597B/me unknown
- 2013-10-01 CN CN201380059974.0A patent/CN104981458B/zh active Active
- 2013-10-01 PL PL13770928T patent/PL2903968T3/pl unknown
- 2013-10-01 CN CN201710513194.9A patent/CN107434803B/zh active Active
- 2013-10-01 WO PCT/EP2013/070457 patent/WO2014053491A1/en not_active Ceased
- 2013-10-01 PL PL15200672T patent/PL3023415T3/pl unknown
- 2013-10-01 EA EA201500394A patent/EA030698B1/ru not_active IP Right Cessation
- 2013-10-01 HU HUE13770928A patent/HUE033380T2/en unknown
- 2013-10-01 SG SG11201502452RA patent/SG11201502452RA/en unknown
- 2013-10-01 RS RS20170216A patent/RS55764B1/sr unknown
- 2013-10-01 ES ES13770928.3T patent/ES2617905T3/es active Active
- 2013-10-01 DK DK13770928.3T patent/DK2903968T3/en active
- 2013-10-01 JP JP2015534985A patent/JP6530313B2/ja active Active
- 2013-10-01 US US14/381,558 patent/US20150203453A1/en active Granted
-
2014
- 2014-08-28 US US14/472,059 patent/US10189787B2/en active Active
-
2015
- 2015-03-19 IL IL237831A patent/IL237831A/en not_active IP Right Cessation
- 2015-04-01 CL CL2015000829A patent/CL2015000829A1/es unknown
- 2015-04-01 PH PH12015500730A patent/PH12015500730A1/en unknown
- 2015-04-28 CR CR20150217A patent/CR20150217A/es unknown
-
2017
- 2017-02-16 SM SM201700109T patent/SMT201700109B/it unknown
- 2017-02-17 US US15/436,055 patent/US10221139B2/en active Active
- 2017-03-07 CY CY20171100297T patent/CY1118695T1/el unknown
- 2017-07-02 IL IL253259A patent/IL253259B/en not_active IP Right Cessation
- 2017-07-19 PH PH12017501306A patent/PH12017501306A1/en unknown
- 2017-11-07 JP JP2017214526A patent/JP2018016661A/ja active Pending
-
2018
- 2018-02-06 AU AU2018200876A patent/AU2018200876C1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253259B (en) | Inhibitors of histone demethylases | |
| IL240439A0 (en) | Inhibitors of histone demethylases | |
| ZA201505007B (en) | Histone demethylase inhibitors | |
| SMT201800070T1 (it) | Inibiorti di istone demetilasi | |
| AP4029A (en) | Inhibitors of beta-secretase | |
| ZA201504294B (en) | Heterocyclic glutaminase inhibitors | |
| PT2680694T (pt) | Inibidores de histona deacetilase | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| IL236963A0 (en) | beta-secretase inhibitors | |
| PL2888228T3 (pl) | Inhibitory oddziaĆywania CD40-TRAF6 | |
| AU2013326554A1 (en) | Inhibitors of histone demethylases | |
| PT2961736T (pt) | Inibidores de histona desmetilases |